I am a
Home I AM A Search Login

Papers of the Week

Papers: 9 May 2020 - 15 May 2020

Animal Studies, Pharmacology/Drug Development

2020 May 13


Soluble epoxide hydrolase inhibitor, TPPU, increases regulatory T cells pathway in an arthritis model.


Trindade-da-Silva CA, Clemente-Napimoga JT, Abdalla HB, Rosa S M, Ueira-Vieira C, Morisseau C, Verri WA, Montalli V A M, Hammock BD, Napimoga MH
FASEB J. 2020 May 13.
PMID: 32400048.


Epoxyeicosatrienoic acids (EET) and related epoxy fatty acids (EpFA) are endogenous anti-inflammatory compounds, which are converted by the soluble epoxide hydrolase (sEH) to dihydroxylethersatrienoic acids (DHETs) with lessened biological effects. Inhibition of sEH is used as a strategy to increase EET levels leading to lower inflammation. Rheumatoid arthritis is a chronic autoimmune disease that leads to destruction of joint tissues. This pathogenesis involves a complex interplay between the immune system, and environmental factors. Here, we investigate the effects of inhibiting sEH with 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU) on a collagen-induced arthritis model. The treatment with TPPU ameliorates hyperalgesia, edema, and decreases the expression of important pro-inflammatory cytokines of Th1 and Th17 profiles, while increasing Treg cells. Considering the challenges to control RA, this study provides robust data supporting that inhibition of the sEH is a promising target to treat arthritis.